Use of PET-CT in pre-surgical staging of colorectal cancer hepatic metastases;Utilidad de la PET-TC en la estadificación previa a la cirugía por metástasis hepáticas de carcinoma colorrectal

Cirugia Espanola

Volumn 84, Issue 2, 2008, Pages 71-77

  Ramos Rubio, Emilio ^a   Martínez, Laura ^a   Gámez, Cristina ^b   Torras, Jaume ^a   Valls, Carles ^a   Rafecas, Antoni ^a   Lladó, Laura ^a   Jorba, Rosa ^a   Ruiz, Sandra ^a   Serrano, Teresa ^a   Fabregat, Joan ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b Instituto de Diagnóstico Por la Imagen   (Spain)

Author keywords

Colorectal cancer; Hepatectomy; Liver metastases; PET CT

Indexed keywords

EID: 48849101820     PISSN: 0009739X     EISSN: 1578147X     Source Type: Journal    
DOI: 10.1016/S0009-739X(08)72137-7     Document Type: Article

References (23)

1. Clavien PA, Selzner M, Rudiger HA, et al. A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning. Ann Surg. 2003;238:843-50; discussion 851-2.
2. Figueras J, Valls C, Rafecas A, et al. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg. 2001;88:980-5.
3. Belghiti J, Hiramatsu K, Benoist S, et al. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg. 2000;191:38-46.
4. Azoulay D, Castaing D, Smail A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg. 2000;231:480-6.
5. Welsh FK, Tilney HS, Tekkis PP, et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer. 2007;96:1037-42.
6. Elias D, Sideris L, Pocard M, et al. Incidence of unsuspected and treatable metastatic disease associated with operable colorectal liver metastases discovered only at laparotomy (and not treated when performing percutaneous radiofrequency ablation). Ann Surg Oncol. 2005;12:298-302.
7. Wiering B, Krabbe PF, Jager GJ, et al. The impact of fluor-18- deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer. 2005;104:2658-70.
8. Gamez C. [Positron emission tomography/computed tomography (PET/CT): present and future of a new imaging technique in oncology]. Cir Esp. 2005;77:111-3.
9. Fernández FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438-47; discussion 447-50.
10. Bipat S, Van Leeuwen MS, Comans EF, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis - meta-analysis. Radiology. 2005;237:123-31.
11. Truant S, Huglo D, Hebbar M, et al. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg. 2005;92:362-9.
12. Rappeport ED, Loft A, Berthelsen AK, et al. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol. 2007;48:369-78.
13. Teague BD, Morrison CP, Court FG, et al. Role of FDG-PET in surgical management of patients with colorectal liver metastases. ANZ J Surg. 2004;74:646-52.
14. Lejeune C, Bismuth MJ, Conroy T, et al. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. J Nucl Med. 2005;46:2020-8.
15. Arulampalam TH, Francis DL, Visvikis D, et al. FDG-PET for the pre-operative evaluation of colorectal liver metastases. Eur J Surg Oncol. 2004;30:286-91.
16. Chapman WC, Hoff PM, Strasberg SM. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement by Charnsangavej et al. Ann Surg Oncol. 2006;13:1269-70.
17. Joyce DL, Wahl RL, Patel PV, et al. Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases. Arch Surg. 2006;141:1220-6; discussion 1227.
18. Khan S, Tan YM, John A, et al. An audit of fusion CT-PET in the management of colorectal liver metastases. Eur J Surg Oncol. 2006;32:564-7.
19. Wiering B, Ruers TJ, Krabbe PF, et al. Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery. Ann Surg Oncol. 2007;14:818-26.
20. Selzner M, Hany TF, Wildbrett P, et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg. 2004;240:1027-34; discussion 1035-6.
21. Zhuang H, Sinha P, Pourdehnad M, et al. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med Commun. 2000;21:793-8.
22. Lubezky N, Metser U, Geva R, et al. The role and limitations of 18-Fluoro-2-deoxy-D: -glucose positron emission tomography (FDGPET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg. 2007;11:472-8.
23. Akhurst T, Kates TJ, Mazumdar M, et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol. 2005;23:8713-6.